Goldman Sachs: Maintains a "neutral" rating on LIVZON PHARMA (01513) with a target price lowered to 20.35 Hong Kong dollars.

Goldman Sachs released a research report stating that LIVZON PHARMA (01513) saw a year-on-year decrease of 1.6% in sales in the fourth quarter of last year, with performance weaker than expected. The current product portfolio has reached a bottleneck, and future growth potential will depend on the development of new products. Based on the latest performance and progress in project research and development, profit forecasts for the next two years have been lowered by 7.3% and 8.2%. The target price for LIVZON PHARMA has been decreased from HK$21.1 to HK$20.35, while the "Neutral" rating is maintained.